97 related articles for article (PubMed ID: 19509160)
1. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Rajeshkumar NV; Tan AC; De Oliveira E; Womack C; Wombwell H; Morgan S; Warren MV; Walker J; Green TP; Jimeno A; Messersmith WA; Hidalgo M
Clin Cancer Res; 2009 Jun; 15(12):4138-46. PubMed ID: 19509160
[TBL] [Abstract][Full Text] [Related]
2. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Arcaroli JJ; Touban BM; Tan AC; Varella-Garcia M; Powell RW; Eckhardt SG; Elvin P; Gao D; Messersmith WA
Clin Cancer Res; 2010 Aug; 16(16):4165-77. PubMed ID: 20682712
[TBL] [Abstract][Full Text] [Related]
3. Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Jones RJ; Young O; Renshaw L; Jacobs V; Fennell M; Marshall A; Green TP; Elvin P; Womack C; Clack G; Dixon JM
Breast Cancer Res Treat; 2009 Mar; 114(2):211-21. PubMed ID: 18409068
[TBL] [Abstract][Full Text] [Related]
4. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
[TBL] [Abstract][Full Text] [Related]
5. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
8. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.
Pham NA; Magalhaes JM; Do T; Schwock J; Dhani N; Cao PJ; Hill RP; Hedley DW
Int J Cancer; 2009 Jan; 124(2):280-6. PubMed ID: 18924149
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
11. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
[TBL] [Abstract][Full Text] [Related]
12. The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Yun HS; Lee J; Kil WJ; Kramp TR; Tofilon PJ; Camphausen K
Mol Cancer Ther; 2021 Sep; 20(9):1672-1679. PubMed ID: 34158343
[TBL] [Abstract][Full Text] [Related]
13. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
14. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
16. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma.
Madan R; Smolkin MB; Cocker R; Fayyad R; Oktay MH
Hum Pathol; 2006 Jan; 37(1):9-15. PubMed ID: 16360410
[TBL] [Abstract][Full Text] [Related]
18. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
[TBL] [Abstract][Full Text] [Related]
19. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells.
Trevino JG; Gray MJ; Nawrocki ST; Summy JM; Lesslie DP; Evans DB; Sawyer TK; Shakespeare WC; Watowich SS; Chiao PJ; McConkey DJ; Gallick GE
Angiogenesis; 2006; 9(2):101-10. PubMed ID: 16871430
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
